|Systematic (IUPAC) name|
|Molecular mass||294.304 g/mol|
|(what is this?)|
PHCCC is a research drug which acts as a glutamate receptor ligand, particularly being a positive allosteric modulator at the mGluR4 subtype, as well as an agonist at mGluR6. It has anxiolytic effects in animal studies. PHCCC and similar drugs have been suggested as novel treatments for Parkinson's disease.
- Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ (December 2003). "(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection". Neuropharmacology 45 (7): 895–906. doi:10.1016/S0028-3908(03)00271-5. PMID 14573382.
- Beqollari D, Kammermeier PJ (July 2008). "The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors". European Journal of Pharmacology 589 (1–3): 49–52. doi:10.1016/j.ejphar.2008.06.054. PMID 18593581.
- Stachowicz K, Kłak K, Kłodzińska A, Chojnacka-Wojcik E, Pilc A (September 2004). "Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats". European Journal of Pharmacology 498 (1–3): 153–6. doi:10.1016/j.ejphar.2004.07.001. PMID 15363989.
- Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ (November 2008). "Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4". Molecular Pharmacology 74 (5): 1345–58. doi:10.1124/mol.108.049551. PMC 2574552. PMID 18664603.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|